In T-ALL and AML, PICALM::MLLT10 fusions are associated with a poor prognosis [5–7], e.g. 5-year overall survival rates of only 26% in patients with PICALM::MLLT10 + AML, which is consistent with the induction failure in our patient. Here, PICALM is linked to acute lymphoblastic leukemia.